End Drug Shortages Alliance reported that the FDA issued immediate-in-effect guidance granting temporary expanded compounding authority under 503A and 503B for 180 days to address a potential supply gap in neonatal starter parenteral nutrition.
Published
Signal category
Legal & Regulatory
Quote
“The FDA issued immediately-in-effect guidance granting temporary expanded compounding authority under 503A and 503B for 180 days”
— End Drug Shortages Alliance team
Company
End Drug Shortages Alliance
Safeguarding patient access to essential medicines.
- Industry
- Hospitals and Health Care
- Company size
- 3 employees
End Drug Shortages Alliance safeguards patient access to essential medicines. When critical drugs run out, children wait for chemotherapy. Grandparents miss doses of life-saving heart medicine. Families face uncertainty while care teams race to find alternatives. These shortages harm the people we love. We commit to ending drug shortages for good. More than 100 organizations make up End Drug Shortages Alliance, from hospitals and patient advocates to GPOs, manufacturers, distributors, and supply chain leaders. When global disruptions strike, our Rapid Response Team activates to guide the flow of essential medicines. We work together to prevent future shortages, with a focus on transparency, reliability, and resiliency. Because patients can't wait.
Founded 2022